Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial

JAMA

Volumn 306, Issue 17, 2011, Pages 1865-1873

  Oken, Martin M ^a   Hocking, Willam G ^b   Kvale, Paul A ^c   Andriole, Gerald L ^d   Buys, Saundra S ^e   Church, Timothy R ^a   Crawford, E David ^f   Fouad, Mona N ^g   Isaacs, Claudine ^h   Reding, Douglas J ^b   Weissfeld, Joel L ⁱ   Yokochi, Lance A ^j   O'Brien, Barbara ^k   Ragard, Lawrence R ^k   Rathmell, Joshua M ^l   Riley, Thomas L ^l   Wright, Patrick ^l   Caparaso, Neil ^m   Hu, Ping ^m   Izmirlian, Grant ^m   Pinsky, Paul F ^m   Prorok, Philip C ^m   Kramer, Barnett S ⁿ   Miller, Anthony B ^o   Gohagan, John K ^m   Berg, Christine D ^m   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MARSHFIELD CLINIC   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^j PACIFIC HEALTH RESEARCH AND EDUCATION INSTITUTE   (United States)

^k WESTAT   (United States)

^l INFORMATION MANAGEMENT SERVICES INC   (United States)

^m NATIONAL INSTITUTES OF HEALTH   (United States)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX RADIOGRAPHY;

EID: 80355129626     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1591     Document Type: Article

References (19)

1. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer: results of the Memorial Sloan-Kettering study in New York. Chest. 1984;86(1):44-53. (Pubitemid 14088027)
2. Tockman MS, Levin ML, Frost JK, BallWC Jr, Stitik FP,Marsh BR. Screening and detection of lung cancer. In: Aisner J, ed. Lung Cancer. New York, Churchill Livingstone; 1985:25-36. Contemporary Issues in Clinical Oncology; vol 3.
3. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE,Muhm JR. Lung cancer screening: the Mayo program. J Occup Med. 1986;28(8):746-750. (Pubitemid 16055356)
4. Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer. 1990;45(1):26-33. (Pubitemid 20032093)
5. National Cancer Institute. Lung cancer trial results show mortality benefit with low-dose CT: Twenty percent fewer lung cancer deaths seen among those who were screened with low-dose spiral CT than with chest X-ray [news conference]. November 4, 2010. http://www.cancer.gov/newscenter/radio- broadcasts. Accessed November 4, 2010.
6. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
7. Hocking WG, Hu P, Oken MM, et al. PLCO Project Team. Lung cancer screening in the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. J Natl Cancer Inst. 2010;102(10):722-731.
8. Prorok PC, Andriole GL, Bresalier RS, et al.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6)(suppl):273S-309S.
9. American Joint Committee on Cancer, American Cancer Society, American College of Surgeons. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
10. Miller AB, Yurgalevitch S, Weissfeld JL; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6)(suppl):400S-406S.
11. Aberle DR, Berg CD, Black WC, et al. National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology. 2011;258(1):243-253.
12. Proschan MA, Lan KKG, Wittes JT. Statistical Monitoring of Clinical Trials: A Unified Approach. New York, NY: Springer-Verlag; 2006.
13. Ahlbom A. Biostatistics for Epidemiologists. Boca Raton, FL: Lewis; 1993.
14. Izmirlian G. Estimation of the relative risk following group sequential procedure based upon the weighted logrank statistic. arXiv 2011; 1102.5088. http://arxiv.org/abs/1102.5088. Accessed 2010 and 2011.
15. SAS/STAT [computer program]. Version 9. Cary, NC: SAS Institute Inc; 2010.
16. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.
17. Chien C-R, Chen TH-H. Mean sojourn time and effectiveness of mortality reduction for lung cancer screening with computed tomography. Int J Cancer. 2008;122(11):2594-2599. (Pubitemid 351590496)
18. Wu D, Erwin D, Rosner GL. Sojourn time and lead time projection in lung cancer screening. Lung Cancer. 2011;72(3):322-326.
19. Pinsky PF. An early- and late-stage convolution model for disease natural history. Biometrics. 2004;60(1):191-198. (Pubitemid 38392631)